Invented by Institute of Medical Biology, China Academy of Medical Sciences. In June, 20021,the first batch of inactivated vaccine of Keweifu novel coronavirus independently developed by Institute of Medical Biology, China Academy of Medical Sciences was put on the market in China for emergency use.

So far, seven COVID-19 vaccines have been approved for marketing or emergency use in China, while eight vaccines have been approved for phase III clinical trials abroad, and 1 mRNA vaccine has been ethically approved abroad.

Vaccine application:

On 2002 1 June1day, WHO announced that China Kexing COVID-19 vaccine was included in the "emergency use list". In the statement, WHO pointed out that Kexing vaccine meets the international standards of safety and effectiveness.

Marian Gerera Simao, Assistant Director-General of WHO, said that the world urgently needs all kinds of COVID-19 vaccines to solve the problem of global vaccine distribution inequality. WHO urges COVID-19 vaccine manufacturers to join the COVID-19 Vaccine Implementation Plan and share their expertise and data, thus contributing to the control of the COVID-19 epidemic.

By June, 20021year, COVID-19 vaccine had been approved and put into use all over the world: two kinds of inactivated vaccines from Sinopharm Group, Kexing biological inactivated vaccine, adenovirus vector vaccine developed by Kangtai Bio, recombinant protein vaccine developed by zhifei Bio and inactivated vaccine developed by Institute of Biology, China Academy of Medical Sciences.

The above contents refer to Baidu Encyclopedia-novel coronavirus Vaccine.